News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
The emergence of new infections in India is a growing concern
Subscribe To Our Newsletter & Stay Updated
